Compare Amylx Pharmaceuticals Inc (AMLX) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Workiva Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Workiva Inc trades at $68.99 (market cap $3.66B). The key difference: Workiva Inc is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | WK | |
|---|---|---|
Market Cap | $2.53B | $3.66B |
Sector | Health | Technology |
52-Week High | $24.19 | $93.31 |
52-Week Low | $7.82 | $44.31 |
Enterprise Value | $2.28B | $3.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
Workiva (WK) trades at $65.14, up 4.98% with strong bullish momentum. The stock shows positive technical signals with recent earnings beats and revenue growth of 19% year-over-year in Q2 2026. Analyst consensus is overwhelmingly bullish with 16 buy ratings and an average price target of $69.00. The company's AI platform expansion and strong subscription growth support continued momentum.
Outlook remains positive with improving profitability and strategic AI investments, though high valuation multiples and RSI levels near 70 suggest potential near-term consolidation. Key risks include execution challenges and competitive pressures in the compliance software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
